Has Christine Kociszewski, APRN received payments from drug or device companies?

Yes. Drug and device makers reported $3,768 in general payments to Christine Kociszewski, APRN across 72 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Christine Kociszewski, APRN did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Christine Kociszewski, APRN come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Christine Kociszewski, APRN

Family · Concord, NHNPI 1659851178

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.6% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Johnson & Johnson at 33.5% of the total. Among family clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,768in general payments, 2019–2025

Across 72 payments — averaging $52.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$1K
Alkermes, Inc.$452
AbbVie$277
Gilead$240
E.r. Squibb & Sons, L.L.C.$204
Otsuka America Pharmaceutical, Inc.$202
plus $1K from 11 others

What the payments were for

Food & beverage$3,753100%
Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson	24	$1,263
Alkermes, Inc.	7	$452
AbbVie	9	$277
Gilead	5	$240
E.r. Squibb & Sons, L.L.C.	2	$204
Otsuka America Pharmaceutical, Inc.	3	$202
GSK	3	$179
Braeburn Inc.	8	$178
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	2	$171
Novo Nordisk	1	$118
Axsome Therapeutics, Inc.	1	$106
AstraZeneca	1	$100
Teva Pharmaceuticals USA, Inc.	1	$97
Neurocrine Biosciences, Inc.	1	$93
Vanda Pharmaceuticals Inc.	2	$44
Idorsia Pharmaceuticals US Inc	1	$23
Takeda Pharmaceuticals U.S.A., Inc.	1	$22

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,768 in reported general payments places this provider in the 95th percentile of 713 family providers in New Hampshire.

See all family providers in New Hampshire →

Medicare billing

Part B allowed, 2024

$17,854

Medicare patients

Services billed

196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
SublocadeBuprenorphine	24	$49,468
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl	268	$27,522
SuboxoneBuprenorphine Hcl/Naloxone Hcl	40	$22,593
ZubsolvBuprenorphine Hcl/Naloxone Hcl	28	$13,115
Buprenorphine Hcl	70	$1,595
Hydroxyzine Hcl	66	$1,163
Trazodone Hcl	54	$637
Ondansetron OdtOndansetron	38	$546
Diazepam	43	$352
Clonidine Hcl	50	$339
Atorvastatin Calcium	18	$264
Ropinirole Hcl	19	$256
Mirtazapine	12	$253
Levetiracetam	11	$242
Cyclobenzaprine Hcl	11	$239

Paid to pharmacies, not to this prescriber.

Other family in Concord

Brant OliverConcord$9K
Scott SabishConcord$8K
Emely QuinonesConcord$3K
Pamela MeyerConcord$2K
Amy KennedyConcord$2K
Julie LaplanteConcord$2K
Tara Delle ChiaieHampton$548K
Wendy WrightAmherst$447K
Richard CareyNashua$51K
Summer BellDerry$16K

See the full list for New Hampshire →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →